Ahmed Soliman, PhD, is a postdoctoral research fellow in the Division of Engineering in Medicine at the Brigham and Women’s Hospital and Harvard Medical School. His research focuses on the biochemical characterization and therapeutic targeting of LRRK2, a gene for which activating mutations are linked with Parkinson’s disease. Using a range of innovative techniques in protein engineering, Dr. Soliman has designed and synthesized molecules capable of disrupting the activation of the LRRK2 protein. He has developed molecular tools, including synthetic membranes called nanodiscs, for studying LRRK2 function and novel strategies for therapeutically targeting pathological LRRK2. Dr. Soliman received a doctorate in cell biochemistry from the University of Groningen in The Netherlands in 2022. He remained there as a postdoctoral fellow and then lecturer until 2023, when he joined the staff at the Brigham and Women’s Hospital and Harvard Medical School.